1-苄基环丁烷羧酸 | 114672-02-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 中文名称: 1-苄基环丁烷羧酸
• 英文名称: 1-benzylcyclobutane-1-carboxylic acid
• 英文别名: 1-benzyl-cyclobutanecarboxylic acid；1-Benzyl-cyclobutancarbonsaeure；1-Benzylcyclobutanecarboxylic acid
• CAS: 114672-02-5
• 化学式: C₁₂H₁₄O₂
• mdl: MFCD11848869
• 分子量: 190.242
• InChiKey: HMKZTNDNIPVLQW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2916399090

反应信息

• 作为反应物：
  描述：

  1-苄基环丁烷羧酸 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 反应 3.5h， 生成 (1-苄基环丁基)甲醇
  参考文献：
  名称：

  Development of a highly selective EP2-receptor agonist. Part 1: identification of 16-hydroxy-17,17-trimethylene PGE2 derivatives

  摘要：

  Design and synthesis of an EP2-receptor selective agonist began with the chemical modification of alpha- and omega-chains of butaprost 1a, which exhibits an affinity for the IP-receptor. Two series of prostaglandin (PG) analogues with a 16-hydroxy-17,17-trimethylene moiety as an omega-chain were identified. Among those tested, 4a,b,e,f,h and 6a,b,e,f,h were found to be highly selective EP2-receptor agonists. Structure activity relationships are discussed. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(01)00369-8
• 作为产物：
  描述：

  1-苄基环丁烷羧酸乙酯 在 乙酸乙酯 、 Sodium sulfate-III 作用下， 以 乙醇 、 sodium hydroxide 为溶剂， 反应 16.0h， 以to give 1-benzyl-cyclobutanecarboxylic acid (340 mg, 65% yield) as a brown oil, which的产率得到1-苄基环丁烷羧酸
  参考文献：
  名称：

  (ALPHA-SUBSTITUTED CYCLOALKYLAMINO AND HETEROCYCLYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES

  摘要：

  本文提供了(α-取代的环烷基氨基或杂环基氨基)嘧啶基和1,3,5-三嗪基苯并咪唑，例如式I的化合物，以及它们的制备、药物组成和用作治疗增生性疾病的药物或药剂的用途。

  公开号：

  US20140088102A1

文献信息

• [EN] SPIRO-FUSED TRICYCLIC MAP4K1 INHIBITORS<br/>[FR] INHIBITEURS DE MAP4K1 TRICYCLIQUES SPIRO FUSIONNÉS
  申请人：BAYER AG

  公开号：WO2021074279A1

  公开（公告）日：2021-04-22

  The present invention relates to Map4K1 inhibitors of formula (I) to pharmaceutical compositions and combinations comprising the compounds according to the invention, and to the prophylactic and therapeutic use of the inventive compounds, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for neoplastic disorders, repectively cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, as a sole agent or in combination with other active ingredients. The present invention further relates to the use, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of protein inhibitors in benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, in neurodegenerative disorders, in inflammatory disorders, in atherosclerotic disorders and in male fertility control.

  本发明涉及式(I)的Map4K1抑制剂，以及包含根据本发明的化合物的药物组合物和组合物，以及创新化合物的预防性和治疗性用途，分别用于制造用于治疗或预防疾病的药物组合物，特别是用于肿瘤性疾病，癌症或与异常MAP4K1信号相关的其他紊乱免疫反应或其他紊乱的疾病，作为单一药剂或与其他活性成分组合使用。本发明还涉及使用，分别用于制造用于治疗或预防良性增生、动脉粥样硬化疾病、败血症、自身免疫疾病、血管疾病、病毒感染、神经退行性疾病、炎症性疾病、动脉粥样硬化疾病和男性生育控制的蛋白抑制剂的药物组合物的用途。
• [EN] CYCLOBUTENEDIONE DERIVATIVES<br/>[FR] DÉRIVÉS DE CYCLOBUTÈNE-DIONE
  申请人：PFIZER LTD

  公开号：WO2010131145A1

  公开（公告）日：2010-11-18

  The present invention relates to compounds of the formula (I): to pharmaceutically acceptable salts therefore and to pharmaceutically acceptable solvates of said compounds and salts, wherein the substituents are defined herein; to compositions containing such compounds; and to the uses of such compounds in the treatment of various diseases, particularly inflammatory conditions.

  本发明涉及以下式(I)的化合物：以及其药学上可接受的盐和所述化合物及盐的药学上可接受的溶剂化物，其中取代基在此处定义；含有这种化合物的组合物；以及这种化合物在治疗各种疾病，特别是炎症性疾病中的用途。
• Pd(II)-Catalyzed Enantioselective C(sp³)–H Borylation
  作者：Jian He、Qian Shao、Qingfeng Wu、Jin-Quan Yu

  DOI：10.1021/jacs.6b13389

  日期：2017.3.8

  Pd(II)-catalyzed enantioselective borylation of C(sp3)-H bonds has been realized for the first time using chiral acetyl-protected aminomethyl oxazoline ligands. This reaction is compatible with carbocyclic amides containing α-tertiary as well as α-quaternary carbon centers. The chiral β-borylated amides are useful synthons for the synthesis of chiral β-hydroxylated, β-fluorinated, and β-arylated carboxylic

  使用手性乙酰基保护的氨基甲基恶唑啉配体首次实现了 Pd(II) 催化的 C(sp3)-H 键的对映选择性硼酸化。该反应与含有α-叔和α-季碳中心的碳环酰胺相容。手性 β-硼酰化酰胺是用于合成手性 β-羟基化、β-氟化和 β-芳基化羧酸的有用合成子。
• Ligand-Promoted Borylation of C(sp³ )H Bonds with Palladium(II) Catalysts
  作者：Jian He、Heng Jiang、Ryosuke Takise、Ru-Yi Zhu、Gang Chen、Hui-Xiong Dai、T. G. Murali Dhar、Jun Shi、Hao Zhang、Peter T. W. Cheng、Jin-Quan Yu

  DOI：10.1002/anie.201509996

  日期：2016.1.11

  palladium‐catalyzed borylation of C(sp3)H bonds. Primary β‐C(sp3)H bonds in carboxylic acid derivatives as well as secondary C(sp3)H bonds in a variety of carbocyclic rings, including cyclopropanes, cyclobutanes, cyclopentanes, cyclohexanes, and cycloheptanes, can thus be borylated. This directed borylation method complements existing iridium(I)‐ and rhodium(I)‐catalyzed CH borylation reactions in terms

  甲喹啉配体的基于有效地促进C的钯-催化的硼化（SP 3） H键。因此，可以使羧酸衍生物中的伯B-C（sp 3）H键以及各种碳环中的仲C（sp 3）pent H键（包括环丙烷，环丁烷，环戊烷，环己烷和环庚烷）进行硼化。此定向硼化方法补充了现有铱（I） -和铑（I） -催化Ç  ħ硼化反应中的范围和操作条件方面。
• <scp>Iridium‐Catalyzed</scp> Enantioselective C(sp ³ )–H Borylation of Cyclobutanes
  作者：Xiang Chen、Lili Chen、Hongliang Zhao、Qian Gao、Zhenlu Shen、Senmiao Xu

  DOI：10.1002/cjoc.202000240

  日期：2020.12

  herein report the first example of iridium‐catalyzed enantioselective C(sp3)–H borylation of cyclobutanes using benzoxazoline as the directing group. The combination of a chiral bidentate boryl ligand and an iridium precursor has found to effectively catalyze C(sp3)–H borylation to afford a variety of cyclobutylboronates with good to excellent enantioselectivities. We also demonstrate the synthetic

  我们在此报告了使用苯并恶唑啉作为导向基团的铱催化环丁烷对映选择性C（sp 3）-H硼化的第一个例子。已发现手性双齿硼烷基配体和铱前体的组合可有效催化C（sp 3）-H硼化反应，从而提供具有良好至优异对映选择性的各种环丁基硼酸酯。通过将立体成因的C-B键转换为其他功能，我们还证明了当前方法的合成效用。